INDIANAPOLIS, IN (July 19, 2004) – New guidelines issued by the American College of Cardiology and the American Heart Association are in favor of using ReoPro in acute heart attack patients who are having a balloon or stenting procedure (PCI). ReoPro is indicated for adjunctive use with PCI for the prevention of cardiac ischemic complications in patients undergoing this procedure.
ReoPro is a member of a class of drugs that target the platelet component of blood clots and reduce the complications associated with blood flow restrictions during coronary intervention.
ReoPro was developed by Centocor of Malvern, Pa., and is manufactured by Centocor, B.V., in Leiden, the Netherlands. Eli Lilly and Company markets and distributes the product worldwide except in Japan.
Centocor is a biopharmaceutical company that creates, acquires and markets therapies that yield long-term benefits for patients and the health care community. Lilly develops pharmaceutical products by applying the latest research from its own laboratories and from collaborations with scientific organizations.
